NCT01843413
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Suspended
Not Applicable
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have lesions greater than 2 cm, but equal to or less than 4 cm in diameter
Exclusions: Patients with leptomeningeal metastases
https://ClinicalTrials.gov/show/NCT01843413